A New Orally Bioavailable Dual Adenosine A2B/A3 Receptor Antagonist with Therapeutic Potential.
โ Scribed by Neil J. Press; et al. et al.
- Publisher
- John Wiley and Sons
- Year
- 2005
- Weight
- 16 KB
- Volume
- 36
- Category
- Article
- ISSN
- 0931-7597
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A series of novel and known 5-substituted 7-amino-2-(2-furyl) [1,2,4]triazolo [1,5a][1,3,5]triazine derivatives were synthesized and tested for adenosine receptor antagonism in radioligand binding assays at all four adenosine receptor subtypes and for inhibition of the agonist-induced cyclic AMP res
The structure-activity relationships (SAR) of alkylxanthine derivatives as antagonists at the recombinant human adenosine receptors were explored in order to identify selective antagonists of A 2B receptors. The effects of lengthening alkyl substituents from methyl to butyl at 1-and 3-positions and